Chanticleer Holdings Inc

Chanticleer — Sonnet BioTherapeutics Holdings — Corporate Update (November 2022)

12 slides from Chanticleer's corporate update, Nov 2, 2022

  1. Slide 1: Powering a New Wave of Immune Therapeutics

    Slide 1: Powering a New Wave of Immune Therapeutics

    POWERING A NEW WAVE OF IMMUNE THERAPEUTICS SON-1010 Clinical Update Presentation November 2, 2022

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS, This presentation contains forward-looking statements about Sonnet. BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “

  3. Slide 3: Sonnet Pipeline Targets: Multiple Points of Intervention

    Slide 3: Sonnet Pipeline Targets: Multiple Points of Intervention

    Sonnet Pipeline Targets Multiple Points of Intervention IL-18 Tumor Antigen news —— e isee ‘\ Lymph | Tumor r Mature Dendritic Fragments el Ce Feoteg autigen Effedtor cells: z ceptors 1. Activate other immune cells 2. Kill “target cells” Activated T-cell Mefnory collet” " Immature 1. Circulate month

  4. Slide 4: Sonnet's Technology Advantage

    Slide 4: Sonnet's Technology Advantage

    Sonnet’s Technology Advantage Flexible Linkers THERAPEUTIC PAYLOAD B IL-12 ‘THERAPEUTIC PAYLOAD A BINDS TO SERUM ALBUMIN 8 oys-34 Z wwe ix F,AB-Albumin ¢ binds FcRn for enhanced pK and TME accumulation ia ne F,AB-Albumin complex binds to GP6O and ‘SPARC in the tumor microenvironment For a video disp

  5. Slide 5: FAB: Accumulation in the Tumor Microenvironment

    Slide 5: FAB: Accumulation in the Tumor Microenvironment

    8 BioThe N NEI erapeutics FAB: Accumulation in the Tumor Microenvironment » 02 a 1 mor stood Vessel vest |} B Albuminiselevated in sod 1. IL-F,AB binds Endothelial rare Albumin in the blood (0) 8 a Celis ie FeRn over expressed in 2. IL-F,,AB — Albumin tumors binds to FeRn resulting in transport from

  6. Slide 6: SON-1010: Reduces Tumor Volume

    Slide 6: SON-1010: Reduces Tumor Volume

    SON-1010: Reduces Tumor Volume IL12-F,yAB (1.3yg) vs IL-12 (30pg) in BL6F10 Melanoma Tumor Volume mm? ~~ Placebo AB IL12-FHAB (1.31g) = molar 0.99 of 1L-12 te IL-12 (30ng) 2857 1500 1:30 ratio of IL-12 1000 Days ‘Single dose when tumor was 100 mm? ; 8 mice/group IL-12 (1yg) and IL12- F,AB (1.39) are

  7. Slide 7: Clinical Program: SB101/SB102 Study Designs

    Slide 7: Clinical Program: SB101/SB102 Study Designs

    Clinical Program: SB101/SB102 Study Designs $B102: SAD for = Rapid enrollment of healthy volunteers in the SAD provides clean PK data without PKIPD/FACS in interpretation challenges from prior cancer Healthy Volunteers Loon eve ] treatment effects peserene * Simulation using continual reassessment =

  8. Slide 8: SB101: Safety Data (unaudited, as of 10/31/22)

    Slide 8: SB101: Safety Data (unaudited, as of 10/31/22)

    SB101: Safety Data (unaudited, as of 10/31/22) Related TEAEs by Grade 0.05 ug/kg (N=3), n (%) 0.15 ug/kg (N=3), n (%) 0.15 > 0.3 ualkg (N=3), n (%) Tachycardia (Grade 1) 1(33.3) Nausea (Grade 1) 183.3) Chills (Grade 1) 1(33.3) Fatigue (Grade 1) 1(33.3) Injection site pain (Grade 1) 1(33.3) 3 (100.0)

  9. Slide 9: SB101: PK and Cytokine Responses

    Slide 9: SB101: PK and Cytokine Responses

    SB101: PK and Cytokine Responses Acute inflammation was assessed with a Luminex bead assay for multiple analytes in both studies IL-12p70 (used to measure SON-1010 concentration) was readily quantitated and shows extended pharmacokinetics Increase in IFNy (showing an IL-12 effect and potential for t

  10. Slide 10: SB101 Swimmers Plot

    Slide 10: SB101 Swimmers Plot

    'SB101 Swimmers Plot © POs Entry © spat entry Days since study start 2 5 of the 6 patients had SD at the first follow-up CT at 2 months, with one patient (#3) progressing (who is now off study). As of the 4- month scan, 2 of the 5 SD patients remained stable, while the others had tumor growth that c

  11. Slide 11: SB101 Clinical Program: High Level Summary

    Slide 11: SB101 Clinical Program: High Level Summary

    SB101 Clinical Program: High Level Summary » Allometric PK modeling suggests ty, in humans is 52 hrs Q Compares favorably with rhIL-12 ty, of 5-12 hrs ci! ] a Early SON-1010 data is consistent with the PK model No Dose Limiting Toxicities to date in 12 patients Mostly mild with very few Grade 2/3 AE

  12. Slide 12: FcAB Platform

    Slide 12: FcAB Platform

    F,,AB Platform SON-1010 (1L12-F,AB) SON-1210 (1L12-F,AB-IL15) Solid Tumors SON-1410 (IL18-F,AB-IL12) Metanoma, Renal Cancers SON-3015 (Ant-IL6-F,AB-Anti-TGFB) Tumorand Bone Metastases Chemotherapy induced Peripheral Neuropathy ‘SON-080 (Low-dose IL-6) Diabetic Peripheral Neuropathy Cure + SB101 and

Source: SEC EDGAR · 8-K filed Nov 2, 2022

More decks from Chanticleer Holdings Inc